Japanese guidance for use of biologics for psoriasis (the 2019 version) - Saeki, Hidehisa; Terui, Tadashi; Morita, Akimichi; Sano, Shigetoshi; Imafuku, Shinichi; Asahina, Akihiko; Komine, Mayumi; Etoh, Takafumi; Igarashi, Atsuyuki; Torii, Hideshi; Abe, Masatoshi; Nakagawa, Hidemi; et al. (Journal of dermatology, 2020)
Keywords: Adalimumab - therapeutic use; Antibodies, Monoclonal - therapeutic use; Antibodies, Monoclonal, Humanized - therapeutic use; Arthritis; Biological products; Biological Products - therapeutic use; biologics; Contraindications, Drug; Dermatologic Agents - administration & dosage; Dermatologic Agents - adverse effects; Dermatologic Agents - therapeutic use; Drug Substitution - standards; Drug Therapy, Combination; Humans; Immunoglobulins; Infliximab; Infliximab - therapeutic use; interleukin‐17; interleukin‐23; Japan; Monoclonal antibodies; Patient Care Planning; Patient Selection; Patients; Psoriasis; Psoriasis - drug therapy; Tumor necrosis factor-α; Ustekinumab - therapeutic use; Japan; interleukin-17; biologics; psoriasis; tumor necrosis factor-α; interleukin-23